SpringerLink
Log in

Therapeutic Proteins and Advanced Therapy Medicinal Products

  • Chapter
  • First Online:
Practical Pharmaceutics

  • 1342 Accesses

Abstract

This chapter is divided in two parts: Therapeutic proteins and Advanced Therapy Medicinal Products (ATMPs).

  • Therapeutic Proteins.

Therapeutic proteins are large molecules that are different from low molecular weight medicines. They consist of amino acid chains, sometimes decorated with polysaccharides (glycoproteins) that fold in space in secondary and tertiary structures. The first section describes the production process which is divided into upstream and downstream processing. It encompasses cell line development and expression of biopharmaceutical products in Upstream Processing (USP), the purification of the products during Downstream Processing (DSP), as well as the subsequent formulation process (which may be part of DSP or done afterwards).

Therapeutic proteins are sensitive to chemical and physical degradation. The formulation section describes the forces that stabilize a therapeutic protein and potential degradation pathways. It then discusses the challenges a formulator encounters when develo** a protein medicinal product: (1) the development of analytical techniques for monitoring critical quality attributes, (2) the selection of the relevant tests to optimize stability and the excipients available, (3) the options for primary packaging materials and (4) the link with the preferred routes of administration. Ultimately, this should lead to achieving the predefined target product formulation profile for a biological.

The predominant routes of administration for therapeutic proteins are the intravenous and subcutaneous (s.c.) route. In contrast to intravenous administration, absorption of the protein from the subcutaneous reservoir upon s.c. injection is an extra step, resulting in a longer time to reach the maximum plasma concentration (Cmax) as compared to intravenous administration.

Therapeutic proteins are very important treatment options for a variety of diseases. An adverse event specifically linked to therapeutic proteins is immunogenicity. An immune response against a therapeutic protein can have a major impact on efficacy and/or safety and can be influenced by either patient-, disease-, and product-related factors. Especially, the product-related factors are important to take into consideration during product development.

  • ATMPs.

The second part of the chapter is devoted to the discussion of Advanced Therapy Medicinal Products (ATMPs). These are medicines made from, or consisting of, cells, genes or tissues. They have introduced a new area of specialism to the pharmacy workforce. The section about ATMPs will explore the role of the pharmacy team in the delivery of ATMPs recognising that operationalising ATMPs requires a collaborative multidisciplinary approach to ensure that the medicines are optimised for patients. This involves ensuring that whilst appropriate pharmacovigilance and pharmaceutical procedures are in place, handling is undertaken by a trained workforce that is competent in the handling of cellular products. The second part describes the legislation applicable to ATMPs and focuses on specific operational considerations including the logistics and product handling requirements related to ATMPs and the implications for pharmacy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Krämer I, Thiesen J, Astier A (2020) Formulation and administration of biological medicinal products. Pharm Res 37(8):1–18

    Article  Google Scholar 

  2. Jackson NA, Kester KE, Casimiro D, Gurunathan S, DeRosa F (2020) The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccine 5(1):1–6

    Article  Google Scholar 

  3. Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov 17(4):261–279

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Jagschies G, Lindskog E, Lacki K, Galliher P (2017) Biopharmaceutical processing, 1st edn. Elsevier. ISBN:9780081006238

    Google Scholar 

  5. Sakuma T, Takenaga M, Kawabe Y, Nakamura T, Kamihira M, Yamamoto T (2015) Homologous recombinant-independent large gene cassette knock-in in CHO cells using TALEN and MMEJ-directed donor plasmids. Int J Mol Sci 16:23849–23866. https://doi.org/10.3390/ijms161023849

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Nemudryi K, Valetdinova S, Medvedev SZ (2014) TALEN and CRISPR/Cas genome editing systems: tools of discovery. Acta Nat 6:19–40

    Article  CAS  Google Scholar 

  7. Lee J, Grav L, Lewis N, Kildegaard H (2015) CRISPR/Cas9-mediated genome engineering of CHO cell factories: application and perspectives. Biotechnol J 10:979–994

    Article  CAS  PubMed  Google Scholar 

  8. Fisher S, Marquart K, Pieper L, Fieder J, Gamer M, Gorr I, Schulz P, Bradl H (2017) miRNA engineering of CHO cells facilitates production of difficult-to-express proteins and increases success in cell line development. Biotechnol Bioeng 114:1495–1510

    Article  Google Scholar 

  9. Ritacco F, Wu Y, Khetan A (2018) Cell culture media for recombinant protein expression in Chinese hamster ovary (CHO) cells: history, key components, and optimization strategies. Biotechnol Prog 34:1407–1426

    Article  CAS  PubMed  Google Scholar 

  10. Bausch M, Schultheiss C, Sieck J (2019) Recommendations for comparison of productivity between fed-batch and perfusion processes. Biotechnol J 14:e1700721. https://doi.org/10.1002/biot.201700721

    Article  CAS  PubMed  Google Scholar 

  11. Gupta A, Amara J, Gousseinov E, Cacace B (2020) Chapter 6: Recent advances in harvest clarification for antibodies and related products. In: Science direct. Approaches to the purification, analysis and characterization of antibody-based therapeutics, pp 117–136. https://doi.org/10.1016/B978-0-08-103019-6.00006-0

    Chapter  Google Scholar 

  12. Wesselingh H, Krijgsman J (2019) Downstream processing in biotechnology, 3rd edn. Delft Academic Press. ISBN:978-90-6562-318-8

    Google Scholar 

  13. Yu et al (2014) Understanding pharmaceutical quality by design. AAPS J 16(4):771–783

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Crommelin Daan JA, Hawe A, Jiskoot W (2018) Formulation of biologics including biopharmaceutical considerations. In: Crommelin Daan JA, Sindelar Robert D, Meibohm B (eds) Pharmaceutical biotechnology, 5th edn. Springer, pp 83–103

    Google Scholar 

  15. Warne NW, Mahler H-C (eds) (2018) Challenges in protein product development, vol 38. AAPS Springer. http://www.springer.com/series/8825

    Google Scholar 

  16. Koulov A. Protein stability and characterization. In: Crommelin DJA, Sindelar RS, Meibohm B, Pharmaceutical biotechnology. 5 Springer; 2018. https://doi.org/10.1007/978-3-030-00710-2

    Chapter  Google Scholar 

  17. Tebbey PW, Varga A, Naill M, Clewell J, Venema J (2015) Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab). MAbs 7(5):805–811. https://doi.org/10.1080/19420862.2015.1073429

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bailey AO, Han G, Phung W et al (2018) Charge variant native mass spectrometry benefits mass precision and dynamic range of monoclonal antibody intact mass analysis. MAbs 10(8):1214–1225. https://doi.org/10.1080/19420862.2018.1521131

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sediq AS, van Duijvenvoorde RB, Jiskoot W, Nejadnik MR (2016) No touching! Abrasion of adsorbed protein is the root cause of subvisible particle formation during stirring. J Pharm Sci 105(2):519–529. https://doi.org/10.1016/J.XPHS.2015.10.003

    Article  CAS  PubMed  Google Scholar 

  20. Lee N, Lee JAJ, Yang H et al (2019) Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. MAbs 11(1):129–144. https://doi.org/10.1080/19420862.2018.1530920

    Article  CAS  PubMed  Google Scholar 

  21. Schoenmaker L, Witzigmann D, Kulkarni JA et al (2021) mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm:120586. https://doi.org/10.1016/j.ijpharm.2021.120586

  22. Beals JM, de Felippis MR, Paavola CD, Allen DP, Garg A, Baldwin DB (2018) Insulin. In: Crommelin Daniel JA, Sindelar Robert D, Bernd M (eds) Pharmaceutical biotechnology, 5th edn. Springer, pp 403–427. https://doi.org/10.1007/978-3-030-00710-2_18

    Chapter  Google Scholar 

  23. Patke S, Gaillat EN, Calero-Rubio C et al (2021) A systematic approach to evaluating closed system drug-transfer devices during drug product development. J Pharm Sci. https://doi.org/10.1016/j.xphs.2021.12.020

  24. Jackisch C, Kim S-B, Semiglazov V, Melichar B, Pivot X, Hillenbach C, Stroyakovskiy D, Lum BL, Elliott R, Weber HA, Ismael G (2015) Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol 26(2):320–325

    Article  CAS  PubMed  Google Scholar 

  25. Quartino AL, Hillenbach C, Li J, Li H, Wada RD, Visich J, Li C, Heinzmann D, ** JY, Lum BL (2016) Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer. Cancer Chemother Pharmacol 77:77–78

    Article  CAS  PubMed  Google Scholar 

  26. Richter WF, Bhansali SG, Morris ME (2012) Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 14(3):559–570. https://doi.org/10.1208/s12248-012-9367-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. EMA. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins 2007. Doc. Ref. CHMP/EWP/89249/2004

    Google Scholar 

  28. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with Infliximab, a tumor necrosis factor α–neutralizing agent. N Engl J Med 345:1098–1104. https://doi.org/10.1056/NEJMoa011110

    Article  CAS  PubMed  Google Scholar 

  29. EMA. Guideline on Immunogenicity assessment of therapeutic proteins 2017. EMEA/CHMP/BMWP/14327/2006 Rev 1

    Google Scholar 

  30. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J-J, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469–475. https://doi.org/10.1056/NEJMoa011931

    Article  CAS  PubMed  Google Scholar 

  31. Doessegger L, Banholzer ML (2015) Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunol 4. https://doi.org/10.1038/cti.2015.14. Wiley Online Library

  32. Fotiou F, Ararvind S (2009) Impact of illegal trade on the quality of epoetin alfa in Thailand. Clin Ther 31:336–346. https://doi.org/10.1016/j.clinthera.2009.02.014

    Article  CAS  PubMed  Google Scholar 

  33. Linkuviene V, Rossb EL, Crawfordc L, Weiserc SE, Mand D, Kayc S, Kolhec P, Carpentera JF (2022) Effects of transportation of IV bags containing protein formulations via hospital pneumatic tube system: particle characterization by multiple methods. J Pharm Sci 111:1024–1039

    Article  CAS  PubMed  Google Scholar 

  34. Vlieland ND et al (2016) The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology 55(4):704–709. https://doi.org/10.1093/rheumatology/kev394

    Article  PubMed  Google Scholar 

  35. Vlieland ND et al (2018) The impact of inadequate temperature storage conditions on aggregate and particle formation in drugs containing tumor necrosis factor-alpha inhibitors. Pharm Res 35(2). https://doi.org/10.1007/s11095-017-2341-x

  36. Gene Therapy Medicinal Products Governance and Preparation Requirement. Version 2 2019. PAN-UK-PWG-for-ATMPs-Gene-Therapy-Guidance-issue-2.pdf (sps.nhs.uk)

    Google Scholar 

  37. Directive 2009/41/EC of the European Parliament and of the Council of 6 May 2009 on the contained use of genetically modified micro-organisms

    Google Scholar 

  38. Black A (2017) (ATMPs)-The role of pharmacy in the successful delivery of advanced therapy medicinal products information for chief pharmacists. Specialist Pharmacy Service 2017

    Google Scholar 

  39. NHS

    Google Scholar 

  40. Hucks G, Rheingold SR (2019) The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL. Blood Cancer J 9:10. https://doi.org/10.1038/s41408-018-0164-6

    Article  PubMed  PubMed Central  Google Scholar 

  41. EMA. European Medicines Agency recommends approval of combined advanced-therapy product. Website accessed July 2022

    Google Scholar 

  42. Black A. Specialist Pharmacy Service (2020). Handling dry ice and vapour phase nitrogen shippers – advice for hospital pharmacies

    Google Scholar 

  43. Professional guidance on the safe and secure handling of medicines. Royal Pharmaceutical Society 2018. https://www.rpharms.com/recognition/setting-professional-standards/safe-and-secure-handling-of-medicines/professional-guidance-on-the-safe-and-secure-handling-of-medicines

  44. PE 010-04: pic/s guide to good practices for the preparation of medicinal products in healthcare establishments

    Google Scholar 

  45. The International Pharmaceutical Federation. Hospital Pharmacy Section Objectives 2019. https://www.fip.org/hospital-pharmacy

  46. Black A. Specialist Pharmacy Service (2020) Out of specification advanced therapy medicinal products. Guidance for Healthcare Organisations. Version 1.2

    Google Scholar 

  47. Black A. Pharmacy Institutional Readiness for Marketed CAR-T Therapy: Guidance for Chief Pharmacists V4 (updated January 2020) – SPS – Specialist Pharmacy Service – The first stop for professional medicines advice

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bioprocess Engineering, Wageningen University, Wageningen, the Netherlands

    Michel Eppink

  2. The Janssen Pharmaceutical Companies of Johnson & Johnson, Leiden, the Netherlands

    Martijn Wapenaar

  3. Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands

    Daan Crommelin

  4. Coriolis Pharma Research GmbH, Martinsried, Germany

    Andrea Hawe

  5. Pharmacy Foundation of Haarlem Hospitals, Haarlem, the Netherlands

    Thijs Giezen

  6. NHS England’s Specialist Pharmacy Service, London, UK

    Anne Black

  7. Kings College Hospital, London, UK

    Alice Tam

Authors
  1. Michel Eppink
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martijn Wapenaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daan Crommelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Hawe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thijs Giezen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anne Black
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alice Tam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne Black .

Editor information

Editors and Affiliations

  1. Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands

    Paul Le Brun

  2. Pharmacy Department, MINT URM Inserm 1066 CNRS 6021, University of Angers, CHU Angers, Angers, France

    Sylvie Crauste-Manciet

  3. Apotheke der Universitätsmedizin, Mainz, Rheinland-Pfalz, Germany

    Irene Krämer

  4. JCS Pharma Consulting Ltd., Newport, Gwent, UK

    Julian Smith

  5. Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands

    Herman Woerdenbag

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Eppink, M. et al. (2023). Therapeutic Proteins and Advanced Therapy Medicinal Products. In: Le Brun, P., Crauste-Manciet, S., Krämer, I., Smith, J., Woerdenbag, H. (eds) Practical Pharmaceutics. Springer, Cham. https://doi.org/10.1007/978-3-031-20298-8_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-20298-8_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-20297-1

  • Online ISBN: 978-3-031-20298-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation